Innovative drugs often mean new treatment options for patients and advances in health care for the American public.
Similar Posts
CDER Conversations
Interviews with experts from FDA’s Center for Drug Evaluation and Research (CDER) on priorities, projects, and initiatives.SV Labs Corporation – 716503 – 12/09/2025
CGMP/Finished Pharmaceuticals/AdulteratedSlade Gorton & Co., Inc, Recalls One Lot of Wellsley Farms Farm-Raised Atlantic Salmon Sold at BJ’s Wholesale Club due to Potential Listeria Monocytogenes Contamination
Waltham, Mass. – Slade Gorton & Co., Inc, is recalling lot 3896 of Wellsley Farms Farm-Raised Atlantic Salmon sold in 2-lb bags at BJ’s Wholesale Club stores due to the potential for the product to be contaminated with Listeria monocytogenes.
Although healthy individuals may suffer only short-term sOlympus Issues Voluntary Labeling Update for Bronchoscopes Used with Laser Therapy Equipment
CENTER VALLEY, Pa., (October 31, 2025) – Olympus Corporation has announced a voluntary, global medical device corrective action to provide further clarification on the safe and effective use of bronchoscopes with laser therapy, argon plasma coagulation or high-frequency cauterization equipment durinChemspec Chemicals Private Limited – 718403 – 12/23/2025
CGMP/Active Pharmaceutical Ingredient (API)/AdulteratedNostrum Laboratories, Inc. Issues Voluntary Nationwide Recall of Sucralfate Tablets USP 1 Gram Within Expiry
Nostrum Laboratories, Inc. (“Nostrum Labs”) filed Chapter 11 bankruptcy on September 30, 2024. In connection with that filing, the company has ceased and shutdown operations and terminated its operational employees at all domestic U.S. sites. Nostrum Labs is initiating a voluntary recall of Sucralfa